You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

CRPC

Showing 1 - 25 of 444
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Castration-resistant Prostate Cancer Trial in Wuxi (Polaprezinc, Abiraterone)

Enrolling by invitation
  • Castration-resistant Prostate Cancer
  • Wuxi, Jiangsu, China
    Jiangnan University
Sep 18, 2022

Treatment Satisfaction With Ra-223 in Japan

Active, not recruiting
  • Prostatic Neoplasms
  • Radium-223 dichloride (Xofigo, BAY88-8223)
  • Multiple Locations, Japan
    Many Locations
Jan 12, 2023

Castrate-Resistant Prostate Cancer Trial in Shanghai (LIGHT-PSMA-CART cells)

Suspended
  • Castrate-Resistant Prostate Cancer
  • LIGHT-PSMA-CART cells
  • Shanghai, Shanghai, China
    Changhai Hospital
Jan 25, 2023

Advanced Prostate Cancer, Metastatic Prostate Cancer, Metastatic Prostate Neuroendocrine Carcinoma Trial in Boston

Not yet recruiting
  • Advanced Prostate Cancer
  • +2 more
  • Boston, Massachusetts
  • +1 more
Sep 25, 2023

Prostatic Adenocarcinoma Trial in Seoul (Enzalutamide)

Not yet recruiting
  • Prostatic Adenocarcinoma
  • Seoul, Korea, Korea, Republic of
    Samsung Medical Center
Aug 23, 2023

Metastatic Castration-resistant Prostate Cancer, mCRPC Trial in Seoul ([177Lu]Ludotadipep)

Recruiting
  • Metastatic Castration-resistant Prostate Cancer, mCRPC
  • Seoul, Korea, Republic of
    The Catholic University of Korea, Seoul, St, Mary's Hospital, 22
Dec 8, 2022

How Radium-223 Dichloride,Alpha Particle-emitting Radioactive

Recruiting
  • Castration-resistant Prostate Cancer
  • Radium-223 dichloride (Xofigo, BAY88-8223)
  • Multiple Locations, Taiwan
    Many locations
Aug 19, 2022

Prostatic Tumor Trial (AAA617, AAA517, Piflufolastat F 18)

Not yet recruiting
  • Prostatic Neoplasm
  • (no location specified)
Apr 27, 2023

Castration-resistant Prostate Cancer Trial in Osaka (Enzalutamide, Flutamide)

Completed
  • Castration-resistant Prostate Cancer
  • Osaka, Japan
    Osaka City University Graduate School of Medicine
Sep 8, 2021

Metastatic Castration-resistant Prostate Cancer Trial ([177Lu]Ludotadipep 3.7 GBq)

Not yet recruiting
  • Metastatic Castration-resistant Prostate Cancer
  • [177Lu]Ludotadipep 3.7 GBq
  • (no location specified)
Jul 12, 2022

Prostate Cancer Trial in Boston (ARN-509, Abiraterone acetate, Prednisone)

Active, not recruiting
  • Prostate Cancer
  • Boston, Massachusetts
    (unnamed)
Jan 17, 2023

Castration Resistant Prostate Cancer, CRPC Trial in Seoul (Cellgram-DC-PC)

Terminated
  • Castration Resistant Prostate Cancer, CRPC
  • Cellgram-DC-PC
  • Seoul, Korea, Republic of
    Asan medical center
Dec 29, 2022

Prostate Cancer Trial in United States (ARN-509 (Phase 1), ARN-509 (Phase 2))

Active, not recruiting
Has Results
  • Prostate Cancer
  • ARN-509 (Phase 1)
  • ARN-509 (Phase 2)
  • San Diego, California
  • +14 more
Jan 17, 2023

Prostate Cancer Metastatic Trial in Leiden (Enzalutamide, 18-FDG PET/CT, Whole body MRI)

Completed
  • Prostate Cancer Metastatic
  • Leiden, Netherlands
    Leiden University Medical Center
Apr 6, 2022

Castration-Resistant Prostate Cancer Trial in Las Vegas, Port Jefferson Station (Enzalutamide or Abiraterone or Apalutamid)

Recruiting
  • Castration-Resistant Prostate Cancer
  • Enzalutamide or Abiraterone or Apalutamid
  • Las Vegas, Nevada
  • +1 more
Apr 4, 2022

Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma Trial in Detroit,

Active, not recruiting
  • Castration Levels of Testosterone
  • +4 more
  • Detroit, Michigan
  • +1 more
Aug 30, 2022

Efficacy After Anti-androgen Therapy for CRPC

Active, not recruiting
  • Castration Resistant Prostate Cancer (CRPC)
    • (no location specified)
    Jan 5, 2021

    Prostatic Tumors Trial in China (Apalutamide, Placebo, Androgen-deprivation Therapy (ADT))

    Recruiting
    • Prostatic Neoplasms
    • Beijing, China
    • +29 more
    Aug 15, 2022

    NSCLC, SCLC, CRPC Trial in Tianjin (JAB-8263)

    Recruiting
    • NSCLC
    • +7 more
    • Tianjin, Tianjin, China
      Tianjin
    Mar 11, 2022

    Prostate Cancer Trial in New York (Abiraterone acetate, Prednisone, Radium-223 dichloride)

    Completed
    • Prostate Cancer
    • Abiraterone acetate
    • +5 more
    • New York, New York
    • +1 more
    Dec 10, 2021

    Castration-resistant Prostate Cancer Trial in Wuxi (Coenzyme A Combined With Abiraterone, Abiraterone)

    Recruiting
    • Castration-resistant Prostate Cancer
    • Wuxi, Jiangsu, China
      Jiangnan University
    Apr 8, 2021

    Prostate Cancer Trial in New Orleans, New York (177Lu-PSMA-617, 68Ga-PSMA-HBED-CC)

    Active, not recruiting
    • Prostate Cancer
    • New Orleans, Louisiana
    • +1 more
    Nov 20, 2021

    Metastatic Prostate Carcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer Trial in Sacramento (Enzalutamide,

    Active, not recruiting
    • Metastatic Prostate Carcinoma
    • +2 more
    • Sacramento, California
      University of California Davis Comprehensive Cancer Center
    Feb 23, 2022

    Metastatic Castration Resistant Prostate Cancer, 68Ga-PSMA PET/CT Positive Trial in Meldola (177Lu-PSMA)

    Unknown status
    • Metastatic Castration Resistant Prostate Cancer
    • 68Ga-PSMA PET/CT Positive
    • Meldola, FC, Italy
      Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumor
    Feb 25, 2021

    Prostatic Cancer, Castration-Resistant Trial in United States (Darolutamide(Nubeqa, BAY1841788), Enzalutamide)

    Completed
    • Prostatic Cancer, Castration-Resistant
    • Portland, Maine
    • +6 more
    Aug 18, 2022